|
|
Article: Pain Market Value Doubles to $5 Billion by 2018.
- Article from:
- BIOTECH Patent News
- Article date:
- August 1, 2008
CopyrightCOPYRIGHT 2008 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The United States market for drug treatment of major neuropathic pain (NP) conditions is currently valued at $2.6 billion, according to US Neuropathic Pain, a report released by WWMR, Inc. (San Mateo, CA).
Growth over the past four years has been driven largely by the successful launch of Lyrica (pregabalin) for diabetic neuropathic pain and post-herpetic neuralgia in December 2004 along with its 2007 approval for fibromyalgia, as well as the launch of Lilly's Cymbalta (duloxetine) for diabetic neuropathic pain in 2004. The additional June 2008 approval of Cymbalta for fibromyalgia will spur penetration of this prevalent condition.
Based on a decade of ...
Related newspaper, magazine, and journal articles:
|
|
Article: US Neuropathic Pain Market Value Doubles to $5 ...
PR Newswire;
September 11, 2008 ;
700+ words
... ... many of whom have neuropathic pain. Worldwide, approximately ... the treatment of neuropathic pain, and are reviewed ... report. Five new neuropathic pain treatments are currently ... milnacipran (Forest Laboratories/Cypress Bioscience ...
|
|